Metabolic Control of Immune-Competency by Odors in <i>Drosophila</i>

Abstract. Background: to evaluate the effects of Vitamin D3 on glyco-metabolic control in type 2 diabetic patients with Vitamin D deficiency. Methods: one hundred and seventeen patients were randomized to placebo and 122 patients to Vitamin D3. We evaluated anthropometric parameters, glyco-metabolic control, and parathormone (PTH) value at baseline, after 3, and 6 months. Results: a significant reduction of fasting, and post-prandial glucose was recorded in Vitamin D3 group after 6 months. A significant HbA1c decrease was observed in Vitamin D3 (from 7.6% or 60 mmol/mol to 7.1% or 54 mmol) at 6 months compared to baseline, and to placebo (p < 0.05 for both). At the end of the study period, we noticed a change in the amount in doses of oral or subcutaneous hypoglycemic agents and insulin, respectively. The use of metformin, acarbose, and pioglitazone was significantly lower (p = 0.037, p = 0.048, and p = 0.042, respectively) than at the beginning of the study in the Vitamin D3 therapy group. The units of Lispro, Aspart, and Glargine insulin were lower in the Vitamin D3 group at the end of the study (p = 0.031, p = 0.037, and p = 0.035, respectively) than in the placebo group. Conclusions: in type 2 diabetic patients with Vitamin D deficiency, the restoration of value in the Vitamin D standard has led not only to an improvement in the glyco-metabolic compensation, but also to a reduced posology of some oral hypoglycemic agents and some types of insulin used.

Download Full-text

Influence of Metabolic Control on Thromboxane Biosynthesis and Plasma Plasminogen Activator Inhibitor Type-1 in Non-insulin-dependent Diabetes mellitus

Thrombosis and Haemostasis ◽

10.1055/s-0038-1650518 ◽

1996 ◽

Vol 76 (01) ◽

pp. 034-037 ◽

Cited By ~ 12

Author(s):

Giovanni Davì ◽

Mario Belvedere ◽

Sergio Vingneri ◽

Isabella Catalano ◽

Carlo Giammarresi ◽

...

Keyword(s):

Diabetes Mellitus ◽

Metabolic Control ◽

Platelet Activation ◽

Macrovascular Disease ◽

Dependent Diabetes Mellitus ◽

Secondary Failure ◽

Diet And Exercise ◽

Strict Diet ◽

Niddm Patients ◽

Pai 1

SummaryWe have previously shown that tight metabolic control by insulin therapy reduced thromboxane-dependent platelet activation in noninsulin-dependent diabetes mellitus (NIDDM) patients. The present study was undertaken to determine whether a similar effect could be obtained without switching diabetics in secondary failure to insulin treatment. For this purpose, we gave strict diet and exercise advise program and adjusted on a weekly basis the oral antidiabetic therapy (glipizide) that 26 patients with NIDDM had been given over the previous months.Basal measurements of urinary ll-dehydro-TXB2 and PAI-1 confirmed previous findings of enhanced levels of these parameters in NIDDM patients with macrovascular disease in comparison to age-and sex-matched controls. After 2-6 weeks, 16 patients achieved tight metabolic control associated with significant reduction of both thromboxane biosynthesis and PAI-1 levels; 10 patients remained in poor control and no significant decrease of both parameters was observed.We conclude that reduction of in-vivo platelet activation and PAI-1 antigen levels after metabolic improvement obtained by frequent reassessment of sulphonylurea therapy together with strict diet and exercise programs may have beneficial effects on the progression of diabetic micro- and macrovascular disease.

Download Full-text

Platelet Behaviour in Non-Insulin-Dependent Diabetes -Influence of Vascular Complications, Treatment and Metabolic Control

Thrombosis and Haemostasis ◽

10.1055/s-0038-1661564 ◽

1986 ◽

Vol 55 (03) ◽

pp. 361-365 ◽

Cited By ~ 8

Author(s):

I Peacock ◽

M Hawkins ◽

S Heptinstall

Keyword(s):

Blood Glucose ◽

Metabolic Control ◽

Platelet Reactivity ◽

Platelet Rich Plasma ◽

Vascular Complications ◽

Adenosine Diphosphate ◽

Glycosylated Haemoglobin ◽

Insulin Dependent Diabetes ◽

Lipid Levels ◽

Insulin Dependent

SummaryPlatelet-rich plasma was prepared from 47 patients with noninsulin-dependent diabetes treated with glibenclamide and metformin, and 21 controls. The release of radio-labelled 5-hydroxy-tryptamine in response to aggregating agents (adenosine diphosphate, adrenaline and sodium arachidonate), and the effects on release of a selective thromboxane inhibitor (UK-34787) were investigated. Subsequently, 20 of the diabetic subjects were chosen at random for treatment with insulin; the remainder continued to take tablets. Platelet studies were then repeated, in all patients, after 4 and 6 months.The results showed an association between platelet behaviour and the presence of vascular complications, and were consistent with previous observations of reduced platelet reactivity in patients taking sulphonylureas. There was no correlation of platelet reactivity with blood glucose, glycosylated haemoglobin or lipid levels.

Download Full-text

Stimulation of residual insulin secretion by glibenclamide in insulin dependent diabetics

Acta Endocrinologica ◽

10.1530/acta.0.0950372 ◽

1980 ◽

Vol 95 (3) ◽

pp. 372-375 ◽

Cited By ~ 5

Author(s):

B. J. Burke ◽

R. J. Sherriff

Keyword(s):

Insulin Secretion ◽

Insulin Therapy ◽

Metabolic Control ◽

C Peptide ◽

Beneficial Effects ◽

Insulin Dependent ◽

Serum And Urine ◽

Stimulation Of

Abstract. Residual insulin secretion, reflected by the presence of C-peptide in serum and urine, has been demonstrated in 5 of 10 insulin-requiring diabetics of less than 10 years' duration tested. The C-peptide response, in the C-peptide secretors, showed a significant increase in both serum and urine after 4 weeks' treatment with 15 mg glibenclamide daily in addition to their usual insulin regime although no beneficial effects in metabolic control were detected. It is suggested that glibenclamide might be a useful adjunct to insulin therapy in insulinrequiring diabetics who still secrete C-peptide.

Download Full-text